Valneva

Valneva EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Valneva (VLA.PA) as of Oct 23, 2026 is -20.47 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 2.67 % — a change of -867.77% (lower).

EBIT/Assets

-20.47 %

YoY

-867.77%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Valneva is 2025 -20.47 % . Operating Income to Assets Ratio (EBIT/Assets) of Valneva was 2024 2.67 % . It decreases by -867.77% lower compared to the previous year.

The Valneva EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
2.72 EUR
Jan 1, 2019
0.57 EUR
Jan 1, 2020
-12.17 EUR
Jan 1, 2021
-6.52 EUR
Jan 1, 2022
-20.28 EUR
Jan 1, 2023
-16.63 EUR
Jan 1, 2024
2.67 EUR
Jan 1, 2025
-20.47 EUR
The Valneva EBIT/Assets history
YEAREBIT/AssetsYoY
-20.47 %-867.77%
2.67 %-116.03%
-16.63 %-18.00%
-20.28 %+211.23%
-6.52 %-46.47%
-12.17 %-2,244.23%
0.57 %-79.15%
2.72 %-230.41%
-2.09 %-89.89%
-20.66 %+185.20%
-7.24 %-30.80%
-10.47 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valneva Stock analysis

What does Valneva do? Valneva SE is a biopharmaceutical company specializing in the development, production, and marketing of vaccines for humans and animals. The company was founded in 2013 through the merger of French biotech company Vivalis and Austrian biotech company Intercell. Valneva focuses on developing vaccines for infectious diseases with a significant global burden but limited commercial demand. They work closely with governments and international organizations to improve access to their vaccines in developing countries. Valneva also has a strong presence in the animal vaccine market, producing vaccines for diseases in livestock and pets. They have developed and marketed several vaccines, including Ixiaro for Japanese encephalitis and VLA15, a vaccine candidate for Lyme disease. Overall, Valneva is an international company with an impressive pipeline of vaccine candidates and a commitment to addressing global health needs. Valneva is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valneva stock

Operating Income to Assets Ratio (EBIT/Assets) of Valneva is -20.47 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Valneva changed from 2.67 % to -20.47 %, representing a -867.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Valneva since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Valneva with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Valneva

All Key Metrics — Valneva